{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:58:29Z","timestamp":1787029109714,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00213-018-4926-4","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T21:04:05Z","timestamp":1526936645000},"page":"2303-2314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Folic acid\/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"235","author":[{"given":"Kenji","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Okuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"4926_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","volume":"39","author":"NC Andreasen","year":"1982","unstructured":"Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784\u2013788","journal-title":"Arch Gen Psychiatry"},{"key":"4926_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1475-2891-13-91","volume":"13","author":"MA Arroll","year":"2014","unstructured":"Arroll MA, Wilder L, Neil J (2014) Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 13:91","journal-title":"Nutr J"},{"key":"4926_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40263-014-0172-4","volume":"28","author":"HE Brown","year":"2014","unstructured":"Brown HE, Roffman JL (2014) Vitamin supplementation in the treatment of schizophrenia. CNS Drugs 28:611\u2013622","journal-title":"CNS Drugs"},{"key":"4926_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2016.03.003","volume":"245","author":"B Cao","year":"2016","unstructured":"Cao B, Wang DF, Xu MY, Liu YQ, Yan LL, Wang JY, Lu QB (2016) Lower folate levels in schizophrenia: a meta-analysis. Psychiatry Res 245:1\u20137","journal-title":"Psychiatry Res"},{"key":"4926_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/00005053-197005000-00009","volume":"150","author":"MW Carney","year":"1970","unstructured":"Carney MW, Sheffield BF (1970) Associations of subnormal serum folate and vitamin B12 values and effects of replacement therapy. J Nerv Ment Dis 150:404\u2013412","journal-title":"J Nerv Ment Dis"},{"key":"4926_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","volume":"74","author":"CU Correll","year":"2017","unstructured":"Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S (2017) Efficacy of 42 pharmacologic Cotreatment strategies added to antipsychotic Monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatr 74:675\u2013684","journal-title":"JAMA Psychiatr"},{"key":"4926_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1017\/S0033291717000022","volume":"47","author":"J Firth","year":"2017","unstructured":"Firth J, Stubbs B, Sarris J, Rosenbaum S, Teasdale S, Berk M, Yung AR (2017) The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. Psychol Med 47:1515\u20131527","journal-title":"Psychol Med"},{"key":"4926_CR8","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/sj.npp.1301391","volume":"32","author":"WW Fleischhacker","year":"2007","unstructured":"Fleischhacker WW, Kemmler G (2007) The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology 32:2435\u20132436","journal-title":"Neuropsychopharmacology"},{"key":"4926_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/0140-6736(90)91942-4","volume":"336","author":"PS Godfrey","year":"1990","unstructured":"Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH (1990) Enhancement of recovery from psychiatric illness by methylfolate. Lancet 336:392\u2013395","journal-title":"Lancet"},{"key":"4926_CR10","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1176\/appi.ajp.161.9.1705","volume":"161","author":"DC Goff","year":"2004","unstructured":"Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161:1705\u20131708","journal-title":"Am J Psychiatry"},{"key":"4926_CR11","unstructured":"Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). In: Collaboration TC (ed). http:\/\/handbookcochrane.org"},{"key":"4926_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2010.12.006","volume":"127","author":"M Hill","year":"2011","unstructured":"Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 127:41\u201345","journal-title":"Schizophr Res"},{"key":"4926_CR13","unstructured":"ISRCTN32434568 (2009) OCTUMI-4: evaluation of mirtazapine and folic acid for schizophrenia"},{"key":"4926_CR14","unstructured":"Kane JM (2012) Treatment options for refractory positive and negative symptoms in schizophrenia. Schizophrenia research 136, S21"},{"key":"4926_CR15","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP (1989) The Positive And Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl:59\u201367","DOI":"10.1192\/S0007125000291514"},{"key":"4926_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1600-0447.1977.tb00174.x","volume":"55","author":"M Krawiecka","year":"1977","unstructured":"Krawiecka M, Goldberg D, Vaughan M (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 55:299\u2013308","journal-title":"Acta Psychiatr Scand"},{"key":"4926_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/acps.12030","volume":"127","author":"FU Lang","year":"2013","unstructured":"Lang FU, Kosters M, Lang S, Becker T, Jager M (2013) Psychopathological long-term outcome of schizophrenia -- a review. Acta Psychiatr Scand 127:173\u2013182","journal-title":"Acta Psychiatr Scand"},{"key":"4926_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174:927\u2013942","journal-title":"Am J Psychiatry"},{"key":"4926_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.biopsych.2005.10.009","volume":"60","author":"J Levine","year":"2006","unstructured":"Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH (2006) Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60:265\u2013269","journal-title":"Biol Psychiatry"},{"key":"4926_CR20","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","volume":"94","author":"SA Lipton","year":"1997","unstructured":"Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94:5923\u20135928","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4926_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"4926_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.mp.4001746","volume":"11","author":"JW Muntjewerff","year":"2006","unstructured":"Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11:143\u2013149","journal-title":"Mol Psychiatry"},{"key":"4926_CR23","unstructured":"NCT00202280 (2005) Efficacy of treating first episode psychosis with folic acid, B12 and B6 in addition to antipsychotic medication (Principal Investigator: Dr Colin P O'Donnel)"},{"key":"4926_CR24","unstructured":"NCT00300404 (2006) Effect of specific anti-toxoplasmatic add-on medcation in toxoplasma gondii seropositive individuals with schizophrenia or major depression. (Principal Investigator: Dunja Hinze-Selch)"},{"key":"4926_CR25","unstructured":"NCT00403247 (2006) Effect of high-dose B-complex vitamins on the symptoms of schizophrenia. (Principal Investigator: William M Greenberg)"},{"key":"4926_CR26","unstructured":"NCT01263080 (2010) Evaluation of mirtazapine and folic acid for schizophrenia: (RECOVERY2). (Principal Investigator: Gang Wang)"},{"key":"4926_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","volume":"131","author":"RE Nielsen","year":"2015","unstructured":"Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131:185\u2013196","journal-title":"Acta Psychiatr Scand"},{"key":"4926_CR28","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/schbul\/sbt154","volume":"40","author":"A Nishi","year":"2014","unstructured":"Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, Tomotake M, Ohi K, Hashimoto R, Imoto I, Takeda M, Ohmori T (2014) Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 40:1154\u20131163","journal-title":"Schizophr Bull"},{"key":"4926_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12881-015-0197-7","volume":"16","author":"S Numata","year":"2015","unstructured":"Numata S, Kinoshita M, Tajima A, Nishi A, Imoto I, Ohmori T (2015) Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis. BMC Med Genet 16:54","journal-title":"BMC Med Genet"},{"key":"4926_CR30","doi-asserted-by":"crossref","unstructured":"Rai V, Yadav U, Kumar P, Yadav SK, Gupta S (2017) Methylenetetrahydrofolate reductase A1298C genetic variant & risk of schizophrenia: A meta-analysis. Indian J Med Res 145(4): 437\u2013447","DOI":"10.4103\/ijmr.IJMR_745_14"},{"key":"4926_CR31","doi-asserted-by":"publisher","first-page":"17573","DOI":"10.1073\/pnas.0803727105","volume":"105","author":"JL Roffman","year":"2008","unstructured":"Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, Goff DC, Manoach DS (2008a) MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proc Natl Acad Sci U S A 105:17573\u201317578","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4926_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.biopsych.2006.12.017","volume":"63","author":"JL Roffman","year":"2008","unstructured":"Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC (2008b) Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 63:42\u201348","journal-title":"Biol Psychiatry"},{"key":"4926_CR33","unstructured":"Roffman JL,Lamberti JS, Achtyes E, Macklin EA,GalendezGC, Raeke LH, Silverstein NJ, Tuinstra D, Hill M, Goff DC (2011) A multicenter investigation of folate plus B12 supplementation in schizophrenia. Neuropsychopharmacology 36, S198\u2013S323"},{"key":"4926_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2013.900","volume":"70","author":"JL Roffman","year":"2013","unstructured":"Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70:481\u2013489","journal-title":"JAMA Psychiatry"},{"key":"4926_CR35","unstructured":"Roffman JL,Lamberti JS, Achtyes E, Macklin EA,Galendez GC, Raeke LH, Tanner AS, Silverstein NJ, Ho NF, Smoller JW, Hill M, Goff DC (2014a) Effects of (6S)-5-methyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid supplementation on cortical thickness in schizophrenia. Neuropsychopharmacology 39, S6"},{"key":"4926_CR36","doi-asserted-by":"crossref","unstructured":"Roffman JL,Lamberti JS, Achtyes E, Macklin EA,GalendezGC, Raeke LH, Tanner AS, Silverstein NJ, Ho NF, Smoller JW, Hill M, Goff DC (2014b) Effects of folic acid and vitamin b12 supplementation on negative symptoms and related MRI indices. Schizophrenia Research 153, S80","DOI":"10.1016\/S0920-9964(14)70259-2"},{"key":"4926_CR37","unstructured":"Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, Giegold M, Silverstein NJ, Bottiglieri T, Manoach DS, Smoller JW, Henderson DC, Goff DC (2017) Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry 23(2):316\u2013322"},{"key":"4926_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/ern.12.143","volume":"13","author":"JJ Rucklidge","year":"2013","unstructured":"Rucklidge JJ, Kaplan BJ (2013) Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review. Expert Rev Neurother 13:49\u201373","journal-title":"Expert Rev Neurother"},{"key":"4926_CR39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53:1119\u20131129","journal-title":"J Clin Epidemiol"},{"key":"4926_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J Os van","year":"2009","unstructured":"van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635\u2013645","journal-title":"Lancet"},{"key":"4926_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fphar.2017.00585","volume":"8","author":"WW Wang","year":"2017","unstructured":"Wang WW, Wang XS, Zhang ZR, He JC, Xie CL (2017) A meta-analysis of folic acid in combination with anti-hypertension drugs in patients with hypertension and Hyperhomocysteinemia. Front Pharmacol 8:585","journal-title":"Front Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-018-4926-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-4926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-4926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:29:10Z","timestamp":1751635750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-018-4926-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4926"],"URL":"https:\/\/doi.org\/10.1007\/s00213-018-4926-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs. Sakuma, Matsunaga, Nomura and Okuya, Kishi, and Iwata declare that they have no direct conflicts of interest relevant to this study. No grant support or other sources of funding were used to conduct this study or prepare this manuscript. Dr. Sakuma has nothing to disclose. Dr. Nomura has received speaker\u2019s honoraria from Meiji, MSD, and Otsuka. Dr. Okuya has received speaker\u2019s honoraria from Meiji. Dr. Matsunaga has received speaker\u2019s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Meiji, MSD, Novartis, Otsuka, and Tanabe-Mitsubishi and has received a Fujita Health University School of Medicine research grant and a grant-in-aid for Young Scientists (B). Dr. Kishi has received speaker\u2019s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, MSD, and Tanabe-Mitsubishi (Yoshitomi) and has received a Health Labour Sciences Research Grant and a Fujita Health University School of Medicine research grant. Dr. Iwata has received speaker\u2019s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has had research grants from GlaxoSmithKline, Meiji, and Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}